# SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract

> **NCT00006351** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 34 (actual)

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- Urethral Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** lonafarnib

## Key facts

- **NCT ID:** NCT00006351
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2001-12
- **Final completion:** —
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006351, "SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00006351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*